GE Healthcare Life Sciences opened a technology laboratory at Stevenage Bioscience Catalyst (SBC), the U.K.’s first open innovation bioscience campus. Sir William Castell, chairman of the Wellcome Trust, oversaw the dedication of the GE Healthcare Life Sciences Technology Laboratory, which is equipped with the company’s tools and technologies for drug discovery, protein science, and bioprocessing research.
Staffed by technical specialists, the new 1,000 sq. ft. laboratory will allow GE Healthcare’s U.K. and European customers to evaluate the company’s technologies to take advantage of the advanced technical training facilities. The lab will also be open to researchers who are based at SBC. This use of GE technologies in an active multi-disciplinary scientific environment will help the company drive the development of new innovations and technologies for life sciences research, according to Kieran Murphy, CEO of GE Healthcare Life Sciences.
“Many of the future advances in medicine will be driven by advances in our understanding of cellular mechanisms at the molecular level,” said Murphy. “I’m delighted that our new laboratory is at the heart of Stevenage Bioscience Catalyst, where we can both demonstrate our latest thinking in technology to the life sciences research community, and share knowledge that will help shape future innovation.”
Co-located with GlaxoSmithKline on the Stevenage campus, SBC is a joint venture between the department of business, innovation, and skills, GlaxoSmithKline, the Wellcome Trust, and the Technology Strategy Board.
The new lab will house a wide range of technologies, including Xcellerex™ tools for biomanufacturing, Wave™ for cell culture, IN Cell 6000 for high content cell analysis, AKTA™ Avant for protein purification and Biacore™ for protein interaction studies.